Trying to work out whether my panel improved or merely rearranged itself, because two of the numbers went the wrong way.
What I am trying to establish is whether an unchanged LDL-C alongside a large triglyceride fall is a good result or a bad one, because ApoB and LDL-C seem to be telling different stories.
Happy to be told the question itself is wrong.
CryptoCarl said:Trying to work out whether my panel improved or merely rearranged itself, because two of the numbers went the wrong way.
Omega-3 index improvement on the lipid panel: often overlooked but my omega-3 index went from 4.2% to 8.2% over 9 months. I supplemented with 2g EPA+DHA daily.
This matters because omega-3s are anti-inflammatory and cardioprotective, complementing the GLP-1 benefits. Target omega-3 index is >8%. Combined with the triglyceride reduction from the medication, my lipid profile is the best it's been in decades.
mike.trainer_LA said:Omega-3 index improvement on the lipid panel: often overlooked but my omega-3 index went from 4.2% to 8.2% over 9 months.
Tracking labs for the lipid panel — here's the panel I get every 3 months and why:
- CMP: glucose, electrolytes, kidney function, liver enzymes
- Lipid panel: total cholesterol, LDL, HDL, triglycerides
- A1C: 3-month glucose average
- hsCRP: inflammatory marker
- CBC: blood counts, anemia screening
- B12, folate, iron: nutritional deficiency screening
- TSH, free T4: thyroid monitoring
- Lipase: pancreatic safety check
Total cost with insurance: about $37 copay. Without insurance, request cash-pay pricing from Quest/Labcorp — usually $162.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsCryptoCarl said:Trying to work out whether my panel improved or merely rearranged itself, because two of the numbers went the wrong way.
This is my experience too, for whatever a second data point is worth. The detail I would add is minor and it is already implied above.
Adding the clinical framing, because it changes how the question reads.
Advanced lipoprotein testing on the lipid panel — going beyond standard lipid panel:
| Marker | Baseline | Month 8 | Clinical Meaning |
|---|---|---|---|
| LDL-P | 1527 | 927 | Particle count (more precise than LDL-C) |
| Small dense LDL | 62% | 35% | Atherogenic pattern |
| Remnant cholesterol | 39 | 16 | Triglyceride-rich lipoproteins |
| oxLDL | 72 | 45 | Oxidative stress marker |
The shift from small dense to large buoyant LDL is particularly important — it represents a fundamental change in the atherogenic profile.